Hospital stocks slip after SC query on steep cancer drug markups
Apollo Hospitals reported results.
· Economic Times Markets, ET Stocks
In a landmark ruling, the Supreme Court of India highlighted troubling markups on cancer drugs enforced by hospitals, urging a probe into reports of patients being directed to specific pharmacies for their medications. Following this announcement, the BSE Hospitals Index faced a steep 5% drop, leading to notable losses for industry giants like Apollo Hospitals and Fortis Healthcare.
The analysis
Apollo Hospitals reported movement of 5%. Those are the figures as filed — what moves the price is how they sit against what the market already expected, not their absolute size.
Against that, the stock is -3.5% on the day at ₹7,643.00, and has returned -13.0% over three months. It sits 16% below its 52-week high. The pharma & healthcare sector has moved +0.1% over the same period, so Apollo Hospitals is running 13.1 points behind its peers.
For Apollo Hospitals, the question is how much of this is already reflected in the price and how much re-rates the pharma & healthcare peer set alongside it.
Why it matters
- With BSE involved, this carries a regulatory dimension that can outlast the immediate market reaction.
Market context
- The company directly in focus is APOLLOHOSP.
- Sector exposure: Pharma & Healthcare.
- The immediate tone of coverage reads negative.
In this story
Related coverage
Stock Market Crash LIVE: Sensex Tanks Over 1,200 Points, Nifty 50 Below 22,200; ITC, JSW Steel, IndiGo Among Top Losers
INR vs USD: Rupee near 97/dollar; how TCS, Sun Pharma, Tata Steel, SRF may gain from weaker currency? Experts explain
Pharma stocks to buy ahead of Q2 results: Acutaas Chemicals, Mankind Pharma, Ipca Labs - Max upside? Target price
Sun Pharma to consider ₹15,000 crore NCD issue; board meeting on 12 October
Valiant Organics among 5 commodity stocks that hit 52-week highs and rallied up to 48% in a month